Autoimmune Diseases / 2017 / Article / Tab 1

Research Article

Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis

Table 1

(a) Proliferative lupus nephritis (PLN) background information on based on electronic medical record chart review. Medians presented with 25% and 75% values in parentheses for continuous data because they were not normally distributed. Some percentages are accompanied by in parentheses. Prednisone dose was <10 mg/d. Other immunosuppression was discontinued at least 6 months before confirmatory kidney biopsy. Not all patients had information available for each laboratory measurement. SLE, systemic lupus erythematosus; PLN, progressive lupus nephritis; LN, lupus nephritis; CNS, central nervous system; RBC, red blood cell; dsDNA, double-stranded DNA; SM, smooth muscle; RNP, ribonucleoprotein; CRP, C-reactive protein; NIH, National Institutes of Health.

Average age (range)36 years old (18–60)

Race
 Caucasian15%
 African American60%
 Other25%

Gender
 Female65%

History of HTN83 (19/23)

History of DM0 (0/23)

Arthralgia70 (16/23)

Dermatologic48 (11/23)

Hematologic53 (12/23)

Cardiac involvement35 (8/23)

CNS involvement9 (2/23)

Lung involvement35 (8/23)

Liver involvement9 (2/23)

Hematuria (>3 RBC phf)100 (23/23)

Proteinuria (>300 mg)100 (23/23)

Nephrotic range proteinuria (>3.5 gm)35 (8/23)

Proteinuria Quantification (average in gm)2.36 (0.380–4.61)

Serum Creatinine (average mg/dl)1.13 (0.6–2.4)

ANA (% positive)96 (22/23)

dsDNA antibody (% positive)82 (18/22)
Average (titer)1 : 320
Average (U/mL peak; )189 (130–228)

dsDNA antibody OR ANA (% positive)100 (23/23)

ANCA (% positive)0 (0/3)

Anti-phospholipid antibody (% positive)38 (8/23)

Anti-SM antibody (% positive)38 (6/16)

Anti-RNP antibody (% positive)50 (8/16)

CRP
 (Average mg/dL)2.1 (0.1–6.6)
 (% >0.8 mg/dL)79 (11/14)

Biopsy (%)
 WHO Class III22 (5/23)
 WHO Class IV78 (18/23)
 WHO Class IV + V35 (8/23)
 Crescent Formation23 (6/23)

Median NIH activity index8

Median NIH chronicity index3

Median SLE disease activity index16

Immunosuppression before biopsy (%)
 Prednisone22 (5/23)
 Hydroxychloroquine39 (9/23)
 Other (cyclophosphamide, mycophenolate mofetil, rituximab)9 (2/23)

(b) Systemic lupus erythematosus (SLE) without lupus nephritis (LN) disease control background information on based on ICD-9 codes provided by the Department of Defense Serum Repository (DoDSR). Laboratory data were not available for these disease control patients.

Average age (range)36 years old (18–60)

Race
 Caucasian15%
 African American60%
 Other25%

Gender
 Female65%

History of HTN36%

History of DM9%

Renal involvement0%

Arthralgia73%

Dermatologic46%

Hematologic41%

Anti-phospholipid positive23%

Cardiac involvement9%

CNS involvement9%

Lung involvement18%

Liver involvement5%

Median SLE disease activity index10

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.